These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

716 related items for PubMed ID: 19233575

  • 1. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus.
    Barros SC, Cruz B, Luís TM, Ramos F, Fagulha T, Duarte M, Henriques M, Fevereiro M.
    Vet Microbiol; 2009 Jun 12; 137(3-4):252-9. PubMed ID: 19233575
    [Abstract] [Full Text] [Related]

  • 2. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F, Maris-Veldhuis M, Daus FJ, Tacken MG, Moormann RJ, van Gennip RG, van Rijn PA.
    Vaccine; 2014 Dec 12; 32(52):7108-14. PubMed ID: 25454873
    [Abstract] [Full Text] [Related]

  • 3. Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle.
    Savini G, Hamers C, Conte A, Migliaccio P, Bonfini B, Teodori L, Di Ventura M, Hudelet P, Schumacher C, Caporale V.
    Vet Microbiol; 2009 Jan 01; 133(1-2):1-8. PubMed ID: 18617335
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J, Hägglund S, Bréard E, Riou M, Zohari S, Comtet L, Olofson AS, Gélineau R, Martin G, Elvander M, Blomqvist G, Zientara S, Valarcher JF.
    Vaccine; 2014 Nov 20; 32(49):6614-21. PubMed ID: 25312275
    [Abstract] [Full Text] [Related]

  • 6. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep.
    Oura CA, Wood JL, Sanders AJ, Bin-Tarif A, Henstock M, Edwards L, Floyd T, Simmons H, Batten CA.
    Vaccine; 2009 Dec 09; 27(52):7326-30. PubMed ID: 19786141
    [Abstract] [Full Text] [Related]

  • 7. Vaccines against bluetongue in Europe.
    Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S.
    Comp Immunol Microbiol Infect Dis; 2008 Mar 09; 31(2-3):101-20. PubMed ID: 17765305
    [Abstract] [Full Text] [Related]

  • 8. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection.
    Calvo-Pinilla E, Rodríguez-Calvo T, Sevilla N, Ortego J.
    Vaccine; 2009 Dec 11; 28(2):437-45. PubMed ID: 19857449
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
    Feenstra F, van Gennip RGP, Maris-Veldhuis M, Verheij E, van Rijn PA.
    J Gen Virol; 2014 Sep 11; 95(Pt 9):2019-2029. PubMed ID: 24914064
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bluetongue vaccines: the past, present and future.
    Bhanuprakash V, Indrani BK, Hosamani M, Balamurugan V, Singh RK.
    Expert Rev Vaccines; 2009 Feb 11; 8(2):191-204. PubMed ID: 19196199
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
    Hamers C, Rehbein S, Hudelet P, Blanchet M, Lapostolle B, Cariou C, Duboeuf M, Goutebroze S.
    Vaccine; 2009 May 11; 27(21):2789-93. PubMed ID: 19366576
    [Abstract] [Full Text] [Related]

  • 15. Production and application of recombinant antibodies to foot-and-mouth disease virus non-structural protein 3ABC.
    Foord AJ, Muller JD, Yu M, Wang LF, Heine HG.
    J Immunol Methods; 2007 Apr 10; 321(1-2):142-51. PubMed ID: 17328909
    [Abstract] [Full Text] [Related]

  • 16. Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue.
    Tacken MGJ, Daus FJ, Feenstra F, van Gennip RGP, van Rijn PA.
    Vaccine; 2015 Oct 13; 33(42):5539-5545. PubMed ID: 26387435
    [Abstract] [Full Text] [Related]

  • 17. The Bluetongue Disabled Infectious Single Animal (DISA) Vaccine Platform Based on Deletion NS3/NS3a Protein Is Safe and Protective in Cattle and Enables DIVA.
    van Rijn PA, Maris-Veldhuis MA, van Gennip RGP.
    Viruses; 2021 May 07; 13(5):. PubMed ID: 34067226
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous detection of antibodies to foot-and-mouth disease non-structural proteins 3ABC, 3D, 3A and 3B by a multiplexed Luminex assay to differentiate infected from vaccinated cattle.
    Clavijo A, Hole K, Li M, Collignon B.
    Vaccine; 2006 Mar 06; 24(10):1693-704. PubMed ID: 16260073
    [Abstract] [Full Text] [Related]

  • 19. Detection of virus infection-associated antigen and 3D antibodies in cattle vaccinated against foot and mouth disease.
    O'Donnell VK, Smitsaart E, Cetra B, Duffy S, Finelli J, Boyle D, Draghi G, Fondevila N, Schudel AA.
    Rev Sci Tech; 1997 Dec 06; 16(3):833-40. PubMed ID: 9567309
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.